&lt;p&gt;To Develop and Validate the Combination of RNA Methylation Regulators for the Prognosis of Patients with Gastric Cancer&lt;/p&gt;

Zhang, Jun; Piao, Haiyan; Wang, Yue; Meng, Xiangyu; Yang, Dong; Zhao, Yan; Zheng, Zhichao

doi:10.2147/ott.s276239

Cited by 13 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The performed analysis of m5C and hm5C regulators based on gene expression levels in PRAD patients pinpointed a strong positive correlation among TET enzymes, which was also reported in earlier studies conducted in gastric cancer [74] and HNSCC [75]. Findings of positive correlation among DNMT enzymes, and between TET3 and DNMT3A genes support the previous results in HNSCC [75] and non-small cell lung carcinoma [76].…”

Section: Discussionsupporting

confidence: 87%

UHRF1, NSUN2, and NEIL1 were Detected as Clinical Biomarker Candidates in Prostate Adenocarcinoma with Potential Roles in Disease Pathogenesis

Kahyaoğulları

Demircan

2021

Preprint

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most commonly diagnosed cancer in men. Expanding evidence suggests a significant association between cancer progression and RNA modifications. However, our knowledge of the link between m5C and hm5C pathways with PCa is limited. Therefore, we aimed to explore the diagnostic and prognostic values of m5C and hm5C regulators in PCa. In this study, genetic alterations in m5C and hm5C regulators were identified using publicly available databases. Differentially expressed genes in these pathways between tumor and nontumor samples, correlation among m5C and hm5C pathway members, and prognostic value of the regulators were evaluated. Furthermore, enrichment of gene ontology (GO) terms and KEGG pathways was carried out. Obtained results unveiled the mRNA level differences as the key genetic alterations for m5C and hm5C regulators between tumor and nontumor samples. UHRF1, TET3, and NEIL1 were significantly upregulated in tumor samples compared to nontumor ones, whereas EGR1 was significantly downregulated. UHRF1, DNMT1, NSUN2, NSUN4, C1orf77, C3orf37, WDR77, NEIL1, and TDG genes were identified as candidate prognostic markers of overall survival. The upregulated genes in patient samples with genetic alterations in m5C and hm5C pathways enriched cell cycle-related processes. In summary, our findings suggest that the m5C and hm5C regulators might play a role in PRAD development by activation of proliferation, and the UHRF1, NSUN2, and NEIL1 genes have the potential to be utilized as clinical biomarkers.

show abstract

Section: Discussionsupporting

confidence: 87%

UHRF1, NSUN2, and NEIL1 were Detected as Clinical Biomarker Candidates in Prostate Adenocarcinoma with Potential Roles in Disease Pathogenesis

Kahyaoğulları

Demircan

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…As the fourth most common cancer worldwide, gastric cancer is a major cause of cancer-related death[ 1 ]. Currently, the number of new gastric cancer cases reported globally accounts for 5.7% of all cancer cases, with 8.2% of patients dying as a result[ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Why MUC16 mutations lead to a better prognosis: A study based on The Cancer Genome Atlas gastric cancer cohort

Huang¹,

Cao²,

Wang³

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND MUC16 , encoding cancer antigen 125, is a frequently mutated gene in gastric cancer. In addition, MUC16 mutations seem to result in a better prognosis in gastric cancer. However, the mechanisms that lead to a better prognosis by MUC16 mutations have not yet been clarified. AIM To delve deeper into the underlying mechanisms that explain why MUC16 mutations signal a better prognosis in gastric cancer. METHODS We used multi-omics data, including mRNA, simple nucleotide variation, copy number variation and methylation data from The Cancer Genome Atlas, to explore the relationship between MUC16 mutations and prognosis. Cox regression and random survival forest algorithms were applied to search for hub genes. Gene set enrichment analysis was used to elucidate the molecular mechanisms. Single-sample gene set enrichment analysis and “EpiDISH” were used to assess immune cells infiltration, and “ESTIMATE” for analysis of the tumor microenvironment. RESULTS Our study found that compared to the wild-type group, the mutation group had a better prognosis. Additional analysis indicated that the MUC16 mutations appear to activate the DNA repair and p53 pathways to act as an anti-tumor agent. We also identified a key gene, NPY1R (neuropeptide Y receptor Y1), which was significantly more highly expressed in the MUC16 mutations group than in the MUC16 wild-type group. The high expression of NPY1R predicted a poorer prognosis, which was also confirmed in a separate Gene Expression Omnibus cohort. Further susceptibility analysis revealed that NPY1R might be a potential drug target for gastric cancer. Furthermore, in the analysis of the tumor microenvironment, we found that immune cells in the mutation group exhibited higher anti-tumor effects. In addition, the tumor mutation burden and cancer stem cells index were also higher in the mutation group than in the wild-type group. CONCLUSION We speculated that the MUC16 mutations might activate the p53 pathway and DNA repair pathway: alternatively, the tumor microenvironment may be involved.

show abstract

“…found RBM15 is part of the WTAP-METTL3 N6-methyladenosine (m6A) methyltransferase complex and participates in M6A modification ( 64 ). Studies on RNA methylation regulators in papillary thyroid carcinoma (PTC) and gastric cancer have shown that RBM15 was significantly positively correlated with a better prognosis ( 65 , 66 ). But in LUAD, the high expression level of RBM15 is related to a poor prognosis ( 67 , 68 ).…”

Section: Rbm Proteins Family Can Use As a Predictor For A Prognosis Of Cancermentioning

confidence: 99%

The RNA-Binding Motif Protein Family in Cancer: Friend or Foe?

Guo

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

The RNA-binding motif (RBM) proteins are a class of RNA-binding proteins named, containing RNA-recognition motifs (RRMs), RNA-binding domains, and ribonucleoprotein motifs. RBM proteins are involved in RNA metabolism, including splicing, transport, translation, and stability. Many studies have found that aberrant expression and dysregulated function of RBM proteins family members are closely related to the occurrence and development of cancers. This review summarizes the role of RBM proteins family genes in cancers, including their roles in cancer occurrence and cell proliferation, migration, and apoptosis. It is essential to understand the mechanisms of these proteins in tumorigenesis and development, and to identify new therapeutic targets and prognostic markers.

show abstract

<p>To Develop and Validate the Combination of RNA Methylation Regulators for the Prognosis of Patients with Gastric Cancer</p>

Cited by 13 publications

References 33 publications

UHRF1, NSUN2, and NEIL1 were Detected as Clinical Biomarker Candidates in Prostate Adenocarcinoma with Potential Roles in Disease Pathogenesis

UHRF1, NSUN2, and NEIL1 were Detected as Clinical Biomarker Candidates in Prostate Adenocarcinoma with Potential Roles in Disease Pathogenesis

Why MUC16 mutations lead to a better prognosis: A study based on The Cancer Genome Atlas gastric cancer cohort

The RNA-Binding Motif Protein Family in Cancer: Friend or Foe?

Contact Info

Product

Resources

About